137863-17-3,
(S)-Methyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate,
valsartan methyl ester,
UNII-7BZQ418Z0J,
7BZQ418Z0J,
CHEMBL326349,
Valsartan impurity E,
L-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, methyl ester,
Valsartan impurity E [USP-MC],
L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester,
SCHEMBL2251,
Valsartan Related Compound E,
CTK8C0950,
DTXSID50468616,
UJTNRXYTECQKFO-QHCPKHFHSA-N,
6620AA,
ANW-65515,
BDBM50282365,
ZINC27079783,
AKOS015899737,
AK102662,
N-(1-Oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-L-valine methyl ester,
SC-44898,
AX8234201,
TC-154260,
ST24036315,
I14-11666,
methyl N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-L-valinate,
Methyl N-pentanoyl-N-{[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valinate,
N-[2 inverted exclamation mark -(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Va,
N-valeryl-N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-(L)-valine methyl ester,
(2S)-2-[Pentanoyl[[2'-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl]amino]-3-methylbutyric acid methyl ester,
(S)-3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid methyl ester,
(S)-Methyl 2-(N-((2\'-(1H-tetrazol-5-yl)-[1,1\'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate,
methyl (2S)-3-methyl-2-[N-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoate,
methyl (2S)-3-methyl-2-[pentanoyl-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoate,
C25H31N5O3,
CS-O-10333,
CID11561462,
N-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Valeryl-(L)-Valine methyl ester,
N-[2'-(1H-Tetrazol-5-yl)biphenyl-4-yl methyl]-N-valeryl-(L)-valine methyl ester 1g,
Methyl (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoate,